Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188299 | 0.94 | HTR7 (0.44) | HTR7HTR1BCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4577229 | 0.92 | HTR7 (0.53) | HTR7HTR1BALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2479633 | 0.85 | HTR7 (0.53) | HTR7HTR1BALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL188652 | 0.83 | CYP1A2 (0.47) | HTR1BCYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL27520110 | 0.81 | L3MBTL1 (0.39) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL316261 | 0.81 | CYP1A2 (0.41) | CYP1A2CYP2C19ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2806331 | 0.81 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL27869504 | 0.81 | ALDH1A1 (0.44) | HTR1BCYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6017158 | 0.81 | KDM4E (0.48) | HTR1BCYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL27639452 | 0.81 | HTR1B (0.43) | HTR1BCYP1A2CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-8575179-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8507505-B2 | Dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| EP-2376494-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376493-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD K.K. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. | 2011-10-06 | — | — | US | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010067886-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE2, WEE1, CDKL1 | HTR7 3138/4885HTR1B 2730/4885CYP1A2 1400/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | HTR7 4068/4885HTR1B 3132/4885CYP1A2 1318/4885 |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE2, WEE1, RPS6KA1 | HTR7 3055/4885HTR1B 2637/4885CYP1A2 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.